ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF
Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 584-593
DOI: 10.1016/j.jcf.2026.04.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Kris De Boeck und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Pediatrics, Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium. Electronic address: chri…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Precision Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Cystic Fibrosis Society.
Abstract (Originalsprache)
Genotype-based drug development has yielded highly effective therapies, notably the triple combinations elexacaftor/tezacaftor/ivacaftor (ETI) and vanzacaftor/tezacaftor/deutivacaftor (VTD), now approved in Europe for people with CF having at least one non-class I variant. However not all these people with CF will respond to ETI or VTD, and a few not under the label may respond. Facilitating opportunities to access for patients with rare variants has required a shift in paradigm toward functional testing-based access. This approach assesses the potential benefit of modulator therapy using in vitro functional assays, either in engineered systems expressing defined CFTR variants (theratyping) or in patient-derived tissues (theranostics). We review theranostics as a critical tool for personalized medicine in CF, highlighting its validation in in vitro models derived from patients' own cells such as human intestinal organoids and human nasal epithelial cells. We discuss the current regulatory landscape regarding modulator approval and propose strategies for improving equitable access to effective treatments for all people with CF. Importantly, we advocate for functional assays to be accepted as standalone evidence of drug efficacy for patients with rare variants. Theranostic approaches remain critical when theratyping has not been achieved, and genetic data is not available or clearly interpretable. Indeed, theranostics has emerged as an essential pillar of CF drug access, complementing genotype-driven strategies. As the field advances, continued validation, standardization, and regulatory integration of in vitro functional assays will be key to ensuring that every person with CF-regardless of their genotype-has the opportunity to benefit from precision therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dept of Pediatrics, Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium. Electronic address: christiane.deboeck@kuleuven.be.
- Respiratory Medicine and French Cystic Fibrosis National Reference Center, Hôpital Cochin, AP-HP. Centre Université Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France; Institut Cochin, Inserm U1016, Univ…
- Dept of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: M.C.Bierlaagh@umcutrecht.nl.
- Northern Ireland Clinical Research Facility, The Wellcome-Wolfson Institute of Experimental Medicine, Queen's University, U Floor, City Hospital, Lisburn Road, Northern Ireland. Electronic address: Kate.hill@qub.ac.uk.
- BioISI - Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande C8 bdg, 1749-016, Lisboa, Portugal. Electronic address: msamaral@ciencias.ulisboa.pt.
- Hadassah Organoid Center, The Hadassah Medical Organization, Jerusalem, 9166100, Israel; Department of Pediatric Gastroenterology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, J…
Förderung
- European Cystic Fibrosis Society
Zitieren
APA
De Boeck, K., Burgel, P. R., Bierlaagh, M., Hill, K., Amaral, M., Birimberg-Schwartz, L., Brewington, J. J., Davies, J. C., Karadag, B., Martin, U., Mense, M., Pedemonte, N., Sharma, N., Tayor-Cousar, J. L., Sermet, I., & Beekman, J. M. (2026). ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF. Journal of Cystic Fibrosis, 25(4), 584-593. https://doi.org/10.1016/j.jcf.2026.04.013
Vancouver
De Boeck K, Burgel PR, Bierlaagh M, Hill K, Amaral M, Birimberg-Schwartz L, et al. ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF. Journal of Cystic Fibrosis. 2026;25(4):584-593. doi:10.1016/j.jcf.2026.04.013
BibTeX
@article{DeBoeck2026,
author = {De Boeck, Kris and Burgel, Pierre-Régis and Bierlaagh, Marlou and Hill, Kate and Amaral, Margarida and Birimberg-Schwartz, Liron and Brewington, John Joseph and Davies, Jane C and Karadag, Bulent and Martin, Ulrich and Mense, Martin and Pedemonte, Nicoletta and Sharma, Neeraj and Tayor-Cousar, Jennifer L and Sermet, Isabelle and Beekman, Jeffrey M},
title = {ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {4},
pages = {584--593},
doi = {10.1016/j.jcf.2026.04.013}
}
EUVIMED